CDX
HT-1080
Tumor indication
Sarcoma
Tumor subtype
Fibrosarcoma
Description
HT-1080 (Fibrosarcoma CDX Model)
The HT-1080 fibrosarcoma line was derived from a human soft tissue sarcoma. It is characterized by mutations in NRAS, reflecting oncogenic drivers of sarcoma progression. HT-1080 has been widely used in preclinical sarcoma studies. Its reproducible growth supports both mechanistic and drug testing research.
Key Features:
- Derived from human fibrosarcoma.
- NRAS-mutant sarcoma model.
- Mesenchymal morphology.
- Robust tumorigenicity in xenografts.
Applications:
HT-1080 supports studies of sarcoma progression and targeted therapy evaluation. Researchers use it to test novel agents directed at RAS signaling. It is also applied in invasion and metastasis research. Its reproducibility makes it a trusted sarcoma model in translational pipelines.
Details
- Tumor indication
- Sarcoma
- Tumor subtype
- Fibrosarcoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.